Skip to main content
SpringerLink
Log in

Neue präklinische Studie zur Wirksamkeit und Sicherheit von CpG-Oligodesoxynukleotiden bei der Alzheimer-Krankheit

A new preclinical study on the efficacy and safety of CpG oligodeoxynucleotides in Alzheimerʼs disease

  • Scientific News
  • Published:
DGNeurologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Klinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland

    M. Pawlowski

Authors
  1. M. Pawlowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Pawlowski.

Additional information

Redaktion

L. Klotz, Münster

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pawlowski, M. Neue präklinische Studie zur Wirksamkeit und Sicherheit von CpG-Oligodesoxynukleotiden bei der Alzheimer-Krankheit. DGNeurologie 4, 412–413 (2021). https://doi.org/10.1007/s42451-021-00365-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42451-021-00365-z

Search

Navigation